Genmab As (GNMSF) Cut to “Sell” at Zacks Investment Research

Genmab As (OTCMKTS:GNMSF) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued on Tuesday.

According to Zacks, “Genmab A/S is a biotechnology company that creates and develops human antibodies for the treatment of life-threatening and debilitating diseases. Genmab has numerous products in development to treat cancer, infectious disease, rheumatoid arthritis and other inflammatory conditions, and intends to continue assembling a broad portfolio of new therapeutic products. In addition, Genmab has developed UniBody, a new proprietary technology that creates a stable, smaller antibody format. Genmab has operations in Europe and the US. “

Separately, JPMorgan Chase & Co. lowered Genmab As from an “overweight” rating to a “neutral” rating in a research report on Friday, October 6th.

Shares of Genmab As (GNMSF) opened at $187.55 on Tuesday. Genmab As has a one year low of $163.00 and a one year high of $239.75. The stock has a market capitalization of $11,370.00 and a price-to-earnings ratio of 60.99.

TRADEMARK VIOLATION WARNING: This piece was first published by Community Financial News and is the property of of Community Financial News. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this piece can be accessed at https://www.com-unik.info/2018/01/11/genmab-as-gnmsf-cut-to-sell-at-zacks-investment-research.html.

About Genmab As

Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer in Denmark and internationally. The company markets Arzerra, a human monoclonal antibody for the treatment of chronic lymphocytic leukemia (CCL); and DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM).

Get a free copy of the Zacks research report on Genmab As (GNMSF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Genmab As Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab As and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit